Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

Related Keywords

,Optimizing Therapy ,Endometrial Cancer ,Recent Data Highlights ,Managing Toxicities ,Lenvatinib ,Pembrolizumab ,Adverse Events ,Toxicities ,Supportive Care ,Treatment Strategies ,Diarrhea ,Hypertension ,Medication Management ,Dose Adjustment ,Patient Comfort ,Overlapping Toxicities ,Pcp Collaboration ,Side Effect Management ,